NFKB1 and myalgic encephalomeyelitis/chronic fatigue syndrome: Balanced TP53 activation could reduce ME/CFS severity by promoting cellular repair (159), regulating metabolic pathways (160), and mitigating inflammation through the suppression of NF-κB transcriptional activity and mast cells and eosinophil-mediated Th2 dominant response (161).